Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PREP | P48147 | 6/20 | 0.55 |
| ▸ | DPP4 | P27487 | 12/20 | 0.54 |
| ▸ | DPP8 | Q6V1X1 | 4/20 | 0.51 |
| ▸ | DPP9 | Q86TI2 | 4/20 | 0.51 |
| ▸ | FAP | Q12884 | 1/20 | 0.49 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4888951 | 0.90 | PREP (0.68) | PREPDPP4DPP8DPP9DPP7 | |
| SCHEMBL4889074 | 0.89 | DPP4 (0.52) | PREPDPP4DPP8DPP9 | |
| SCHEMBL4899042 | 0.88 | PREP (0.68) | PREPDPP4DPP8DPP9 | |
| SCHEMBL4669072 | 0.88 | DPP4 (0.53) | PREPDPP4DPP8DPP9FAP | |
| SCHEMBL4893801 | 0.87 | DPP4 (0.57) | PREPDPP4DPP8DPP9DPP7 | |
| SCHEMBL4896136 | 0.87 | DPP4 (0.53) | PREPDPP4DPP8DPP9 | |
| SCHEMBL4893396 | 0.87 | DPP4 (0.57) | PREPDPP4DPP8DPP9 | |
| SCHEMBL4893262 | 0.87 | PREP (0.52) | PREPDPP4DPP8DPP9 | |
| SCHEMBL4889041 | 0.86 | PREP (0.57) | PREPDPP4DPP8DPP7 | |
| SCHEMBL4635280 | 0.86 | PREP (0.57) | PREPDPP4DPP8DPP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080300251-A1 | Derivatives of 3-Azabicyclo[3.1.0] Hexane as Dipeptidyl Peptidase-IV Inhibitors | RANBAXY LABORATORIES LIMITED (IN) | 2008-12-04 | — | — | US | claimed |
| US-20080300251-A1 | Derivatives of 3-Azabicyclo[3.1.0] Hexane as Dipeptidyl Peptidase-IV Inhibitors | RANBAXY LABORATORIES LIMITED (IN) | 2008-12-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080300251-A1 | Derivatives of 3-Azabicyclo[3.1.0] Hexane as Dipeptidyl Peptidase-IV Inhibitors | DPP4, DPP3, DPP8 | PREP 21/4885DPP4 1/4885DPP8 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.